Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

0.8889 +0.0089 (+1.01%)
Streaming Delayed Price Updated: 11:37 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... 
Via Newsfile
Topics Regulatory Compliance
News headline image
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... 
Via Newsfile
Topics Regulatory Compliance
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
Via Investor Brand Network
News headline image
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a... 
Via Newsfile
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Fiscal 2024 Financial Results, Provides Business Update
Via Investor Brand Network
Topics Intellectual Property
CBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth
Via Investor Brand Network
Topics Cannabis
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
Via Investor Brand Network
BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via CannabisNewsWire
Topics Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via Investor Brand Network
Topics Cannabis
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via CannabisNewsWire
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference
Via Investor Brand Network
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results, Business Update
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board
Via Investor Brand Network
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
Via Investor Brand Network
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.